Media Articles Related to Kineret (Anakinra)
Anakinra does not seem to improve fatigue severity in women with chronic fatigue syndrome
Source: Sleep / Sleep Disorders / Insomnia News From Medical News Today [2017.03.09]
The anti-inflammatory biologic drug anakinra does not seem to reduce fatigue severity in women with chronic fatigue syndrome (CFS).
Rheumatoid Arthritis Drug May Not Ease Chronic Fatigue Syndrome After All
Source: MedicineNet Chronic Fatigue Syndrome Specialty [2017.03.07]
Title: Rheumatoid Arthritis Drug May Not Ease Chronic Fatigue Syndrome After All
Category: Health News
Created: 3/6/2017 12:00:00 AM
Last Editorial Review: 3/7/2017 12:00:00 AM
Rheumatoid arthritis: New treatment option for difficult-to-treat patients
Source: Arthritis / Rheumatology News From Medical News Today [2017.03.03]
Between 3 and 5% of the population suffer from a form of inflammatory rheumatism. It affects approximately 250,000 - 400,000 people in Austria.
Pitt bioinformatics study provides clues to relationship between schizophrenia and rheumatoid arthritis
Source: Arthritis / Rheumatology News From Medical News Today [2017.02.28]
An in-depth computational analysis of genetic variants implicated in both schizophrenia and rheumatoid arthritis by researchers at the University of Pittsburgh points to eight genes that may...
Remicade for Rheumatoid Arthritis Treatment
Source: MedicineNet infliximab Specialty [2017.02.23]
Title: Remicade for Rheumatoid Arthritis Treatment
Category: eMedicineHealth Doctor's Perspective
Created: 1/6/2001 12:00:00 AM
Last Editorial Review: 2/23/2017 12:00:00 AM
Published Studies Related to Kineret (Anakinra)
Effects of Prolastin C (Plasma-Derived Alpha-1 Antitrypsin) on the acute
inflammatory response in patients with ST-segment elevation myocardial infarction
(from the VCU-alpha 1-RT pilot study). 
Alpha-1 antitrypsin (AAT) has broad anti-inflammatory and immunomodulating
properties in addition to inhibiting serine proteases... In conclusion, a single administration of Prolastin C in
patients with STEMI is well tolerated and is associated with a blunted acute
Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in
patients with heart failure and preserved ejection fraction (from the D-HART
pilot study). 
Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome of
exercise intolerance due to impaired myocardial relaxation and/or increased
stiffness. Patients with HFpEF often show signs of chronic systemic inflammation,
and experimental studies have shown that interleukin-1 (IL-1), a key
proinflammatory cytokine, impairs myocardial relaxation...
Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study. [2011.07]
CONTEXT: Obesity induces low-grade inflammation that may promote the development of insulin resistance. IL-1 is one of the key inflammatory factors. OBJECTIVE: The objective of the study was to demonstrate improvement of insulin sensitivity by blocking IL-1... CONCLUSIONS: Our results suggest that anakinra does not improve insulin sensitivity in obese, insulin-resistant, nondiabetic subjects.
A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). [2011.05]
OBJECTIVES: To assess the efficacy of the interleukin 1 receptor antagonist anakinra in systemic-onset juvenile idiopathic arthritis (SJIA)... CONCLUSIONS: Anakinra treatment is effective in SJIA, at least in the short term. It is associated with normalisation of blood gene expression profiles in clinical responders and induces a de novo IFN signature. Trial Registration Number: NCT00339157.
Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). [2010.05.15]
Acute myocardial infarction (AMI) initiates an intense inflammatory response in which interleukin-1 (IL-1) plays a central role...
Clinical Trials Related to Kineret (Anakinra)
A Pilot Study Using Anakinra/Kineret for the Treatment of Patients With Severe Atopic Dermatitis [Terminated]
- Severe atopic dermatitis, also known as eczema, is a chronic inflammatory skin
condition that affects both children and adults and causes severe itching and skin
redness. Current treatments of atopic dermatitis include topical creams and lotions,
light therapy, and medications. However, the difficulty with long-term treatment for
the chronic and severe nature of the disease requires more effective and
better-tolerated therapeutic options.
- Anakinra is a drug that blocks a substance called interleukin-1 (IL-1), which may be
important in causing the inflammation in atopic dermatitis. Researchers are interested
in determining whether anakinra can be used to help treat atopic dermatitis. Anakinra
has been approved by the Food and Drug Administration to treat rheumatoid arthritis in
adults and children, but it has not been approved for use in adults or children with
atopic dermatitis and is considered an experimental treatment in this study. In this
study Anakinra will be administered as an injection under the skin every day for 3
- To assess the safety and effectiveness of using anakinra to treat severe atopic dermatitis
- Children between 10 and 18 years of age who have been diagnosed with severe atopic
dermatitis that has not responded to standard treatment.
- Initial Screening: Participants will have an initial screening visit with a complete
physical examination and medical history, blood and urine tests, photographs of the
skin ,skin biopsy, and other tests as required.
- Run-in Period: At the screening visit, participants will receive a diary card and will
be asked to track their atopic dermatitis symptoms on standard treatment for 2 months.
- Start of Treatment: At the end of the 2 month Run-in period participants will return
for an inpatient visit (2 days) to receive the initial dose of anakinra and will be
watched for any side effects. During the inpatient visit, participants will have
additional examinations and blood and urine tests, and will be instructed on how to
administer the anakinra injections at home.
Treatment Period: - Participants will return once a week for the first 2 weeks of treatment,
at the end of the first month, and then once a month for the following 2 months, for a
physical exam and blood tests. Participants will be asked to record symptoms related to
their atopic dermatitis, anakinra administration and any side effects related to the
anakinra on the diary card. The diary cards will be reviewed and collected at each visit.-
End of Treatment Period: At the end of 3 months of treatment with anakinra, participants
will again be asked to record symptoms related to their atopic dermatitis on the diary card.
Participants will be seen once a month for 3 months for a physical exam, blood tests and
review of the diary card. . The final study visit will take place at the end of the 3rd
month and will include a physical exam, blood tests, photographs and skin biopsy.
Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease [Recruiting]
Kawasaki disease (KD) is the leading cause of acquired heart disease in children in the
developed world. Despite available treatment, 25% of children in San Diego County
appropriately treated for KD develop coronary artery abnormalities that may lead to
complications later in life, including heart attack. Although the investigators can identify
children with KD that have these coronary artery abnormalities, there is no approved
additional treatment to decrease coronary artery inflammation and arrest or prevent damage
to the coronary arteries. Anakinra, a therapy that blocks the high levels of interleukin 1
(IL1) that lead to inflammation during acute KD, has been shown in the KD mouse model to
prevent the development of coronary artery damage. Therefore, the investigators propose to
study the safety and activity of anakinra in infants and children < 2 years old with
coronary artery abnormalities from KD.
Anakinra or Denosumab and Everolimus in Advanced Cancer [Recruiting]
The goal of this clinical research study is to find the highest tolerable dose of the
combination of Afinitor (everolimus) either with Kineret (anakinra) or Xgeva (denosumab)
that can be given to patients with advanced cancer. The safety of these drugs will also be
Everolimus is designed to stop cells from dividing.
Anakinra is designated to block a protein that is involved in tumor development, new blood
vessels growing, and spread of cancer.
Denosumab is designed to block the activity of a protein, which may prevent bone
complications in cancer that has spread to the bone.
The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria [Completed]
An open labelled trial of Kineret (anakinra) induction therapy (100mg./day) in over a four
week period in the treatment of Familial Cold Urticaria.
Familial Cold Urticaria (FCU) is a rare autosomal dominant condition manifesting symptoms
triggered by exposure to cold and variable in expression. Currently there is no standard
reliable agent available for the treatment of patients with FCU. This study will evaluate the
efficacy of Kineret (anakinra), an interleukin 1 receptor antagonist in induction and
maintenance therapy in patients with FCU.
Anakinra (Kineret®) in Combination With Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Subjects With Active Rheumatoid Arthritis (RA) [Completed]
The purpose of this study is to evaluate the percentage of subjects in Australian clinical
practice continuing treatment with Anakinra (Kineret®) at the end of study week 48 in
subjects with active RA. The continued use of Kineret® will be based on pre-defined
response assessment criteria for subjects with active RA.
Reports of Suspected Kineret (Anakinra) Side Effects
Alanine Aminotransferase Increased (6),
Cytolytic Hepatitis (4),
Aspartate Aminotransferase Increased (4),
Liver Injury (3),
Drug Ineffective (3), more >>